Cargando…

E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis

The prognostic role of epithelial cadherin (E-cadherin) downregulation in ovarian cancer has been assessed for years while the results remain inconclusive. The aim of our study was to assess this issue. Eligible studies were identified through searches of PubMed, EMBASE and Cochrane Database. In tot...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Chencheng, Cao, Jian, Zeng, Yu, Xu, Sujuan, Jia, Xuemei, Xu, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655261/
https://www.ncbi.nlm.nih.gov/pubmed/29113366
http://dx.doi.org/10.18632/oncotarget.18898
_version_ 1783273499699183616
author Dai, Chencheng
Cao, Jian
Zeng, Yu
Xu, Sujuan
Jia, Xuemei
Xu, Pengfei
author_facet Dai, Chencheng
Cao, Jian
Zeng, Yu
Xu, Sujuan
Jia, Xuemei
Xu, Pengfei
author_sort Dai, Chencheng
collection PubMed
description The prognostic role of epithelial cadherin (E-cadherin) downregulation in ovarian cancer has been assessed for years while the results remain inconclusive. The aim of our study was to assess this issue. Eligible studies were identified through searches of PubMed, EMBASE and Cochrane Database. In total, 1562 patients from 17 studies were included to assess the association between E-cadherin expression and overall survival/progression-free survival and clinicopathological characteristics of ovarian cancer patients. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to estimate the effect. The quality of 17 studies was evaluated using the Newcastle Ottawa Quality Assessment Scale. We also performed subgroup analysis, publication bias and sensitivity analysis in this meta-analysis. The results showed that negative E-cadherin expression significantly predicted poor overall survival of ovarian cancer patients (HR = 1.90, 95% CI = 1.50–2.40). However, negative E-cadherin was not associated with poor progression-free survival (HR = 1.19, 95% CI = 0.86–1.64). Moreover, Negative E-cadherin expression was distinctly associated with FIGO stage (OR = 0.42, 95% CI = 0.31–0.57), tumor grade (OR = 0.48, 95% CI = 0.34–0.67), metastasis (OR = 0.13, 95% CI = 0.07–0.26) and recurrence (OR = 0.48, 95% CI = 0.29–0.79). This meta-analysis revealed that negative E-cadherin expression might be a predicative factor of poor prognosis in ovarian cancer patients.
format Online
Article
Text
id pubmed-5655261
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56552612017-11-06 E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis Dai, Chencheng Cao, Jian Zeng, Yu Xu, Sujuan Jia, Xuemei Xu, Pengfei Oncotarget Meta-Analysis The prognostic role of epithelial cadherin (E-cadherin) downregulation in ovarian cancer has been assessed for years while the results remain inconclusive. The aim of our study was to assess this issue. Eligible studies were identified through searches of PubMed, EMBASE and Cochrane Database. In total, 1562 patients from 17 studies were included to assess the association between E-cadherin expression and overall survival/progression-free survival and clinicopathological characteristics of ovarian cancer patients. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to estimate the effect. The quality of 17 studies was evaluated using the Newcastle Ottawa Quality Assessment Scale. We also performed subgroup analysis, publication bias and sensitivity analysis in this meta-analysis. The results showed that negative E-cadherin expression significantly predicted poor overall survival of ovarian cancer patients (HR = 1.90, 95% CI = 1.50–2.40). However, negative E-cadherin was not associated with poor progression-free survival (HR = 1.19, 95% CI = 0.86–1.64). Moreover, Negative E-cadherin expression was distinctly associated with FIGO stage (OR = 0.42, 95% CI = 0.31–0.57), tumor grade (OR = 0.48, 95% CI = 0.34–0.67), metastasis (OR = 0.13, 95% CI = 0.07–0.26) and recurrence (OR = 0.48, 95% CI = 0.29–0.79). This meta-analysis revealed that negative E-cadherin expression might be a predicative factor of poor prognosis in ovarian cancer patients. Impact Journals LLC 2017-06-30 /pmc/articles/PMC5655261/ /pubmed/29113366 http://dx.doi.org/10.18632/oncotarget.18898 Text en Copyright: © 2017 Dai et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Meta-Analysis
Dai, Chencheng
Cao, Jian
Zeng, Yu
Xu, Sujuan
Jia, Xuemei
Xu, Pengfei
E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
title E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
title_full E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
title_fullStr E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
title_full_unstemmed E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
title_short E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
title_sort e-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655261/
https://www.ncbi.nlm.nih.gov/pubmed/29113366
http://dx.doi.org/10.18632/oncotarget.18898
work_keys_str_mv AT daichencheng ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis
AT caojian ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis
AT zengyu ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis
AT xusujuan ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis
AT jiaxuemei ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis
AT xupengfei ecadherinexpressionasaprognosticfactorinpatientswithovariancancerametaanalysis